QP Code:102516	Reg. No.:

D.M. (Pediatric Oncology) Degree Regular/Supplementary Examinations November 2023

Paper II – Clinical Paediatric Oncology Part I (Hematological Malignancies and Supportive Care)

Time: 3 hrs Max marks:100

- Answer all questions to the point neatly and legibly Do not leave any blank pages between answers • Indicate the question number correctly for the answer in the margin space
- Answer all parts of a single question together Leave sufficient space between answers
- Draw table/diagrams/flow charts wherever necessary

Essay: (20)

 Strategies for managing acute myeloid leukemia (non-M3) in low-middle income countries. How will you optimize management if optimal access to risk stratification, supportive care, and HSCT are lacking.

Short essays: (8x10=80)

- 2. Role of surveillance cultures in Pediatric oncology.
- 3. Prevalence of TPMT, ITPA, and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in Indian children with acute lymphoblastic leukemia.
- 4. Discuss the role, pros, and cons of pooled granulocyte concentrate from whole blood buffy coats vs. granulocytes concentrate obtained by apheresis.
- 5. Discuss the role of trametinib and vemurafenib in the management of LCH.
- 6. Discuss the discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
- 7. Strategies for optimal maintenance chemotherapy for pediatric acute lymphoblastic leukemia to reduce the risk of relapse and severe infections.
- 8. Discuss the pros and cons of ABVD vs. OEPA/COPDAC for pediatric Hodgkin lymphoma in low-middle income countries.
- 9. List the specific indications for allogeneic hematopoietic transplant in the management of acute lymphoblastic leukemia in children.
